Urs H. Flueckiger, Roche Korea's president said in his e-mail interview with Health Korea news on 26 August, "Roche hasn't got in contact with the Korean Ministry for Health, Welfare and Family Affairs(MHWFA) regarding the compulsory licensing of Tamiflu and has no plan to communicate with the South Korean government, even in the furture.
He also said, "Roche's annual production capacity of Tamiflu of 400 million treatments couldn't be enough to cover the population of the whole world. But we have enough Tamiflu to supply to South Korea. It is going to be supplied to South Korean government on time."
Those remarks could be interpreted as a kind of Roche's rejection of South Korean government's demand, if any, for additional purchase of Tamiflu. [헬스코리아뉴스]
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지